Drug taking is against the law.
吸毒是违法的。
They drugged the guard dog.
他们给看门狗下了药。
She was arrested for taking
drugs.
她因吸毒而被捕。
She took the medication as prescribed to treat her headache.
她按照医生的指示服药来治疗头痛。
He's battling a serious addiction to prescription
drugs.
他正在与处方药物严重成瘾作斗争。
The drug was found to be effective in reducing anxiety levels.
这种药物被发现能有效降低焦虑水平。
The police seized a large cache of illegal
drugs during a raid.
警方在突袭中缴获了大量的非法毒品。
The doctor recommended a non-addictive pain reliever for her backache.
医生建议她使用一种非成瘾性的止痛药来缓解背痛。
Many people struggle with the withdrawal symptoms when quitting
drugs cold turkey.
许多人戒毒时会经历强烈的戒断症状。
Drug testing is mandatory for athletes to ensure fair competition.
运动员必须接受药物检测以保证公平竞争。
The government has launched a campaign to combat drug abuse in schools.
政府发起了一项运动，以打击学校里的吸毒行为。
He was arrested for possession of small amounts of recreational
drugs.
他因持有少量娱乐用毒品被捕。
The drug trial showed promising results, but more research is needed.
药物试验显示出了积极的前景，但还需要更多的研究。
In March, Shanghai Junshi Biosciences Co Ltd announced collaboration with Singapore-based Rxilient Biotech on development and commercialization of an antibody drug through a joint venture in nine Southeast Asian nations — Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines and Vietnam.
今年3月，上海君实生物科技有限公司宣布，通过在泰国、文莱、柬埔寨、印度尼西亚、老挝、马来西亚、缅甸、菲律宾和越南等九个东南亚国家的合资企业，与新加坡的Rxilent Biotech合作开发抗体药物并将其商业化。
Li Ning, CEO of Junshi Biosciences, said, "Southeast Asia boasts a thriving pharmaceutical innovation environment, flexible drug regulatory policies and diversified medical security systems, so it has great potential as an emerging market for innovative drugs.
君实生物首席执行官李宁表示：“东南亚拥有繁荣的医药创新环境、灵活的药品监管政策和多样化的医疗保障体系，因此它作为创新药物的新兴市场具有巨大潜力。
"The company said it is planning to launch the antibody drug in more markets.
该公司表示，计划在更多市场推出这种抗体药物。
At the end of last year, the product was approved by the United States Food and Drug Administration.
去年年底，该产品获得了美国食品药品监督管理局的批准。
"From Rxilient to PharmaGend, a closed loop for Chinese pharmaceutical companies' 'new globalization' path is gradually formed — new domestic drugs are produced using Singapore as a development platform and sold on the global market," Zhang said.
张说：“从Rxiient到PharmaGend，中国制药公司‘新全球化’道路的闭环正在逐步形成——以新加坡为开发平台生产国产新药，并在全球市场上销售。”。
As an important hub of both global pharmaceutical research and development and production, Singapore presents higher requirements for drug enterprises' R&D capability, product quality and international compliance.
作为全球药物研发和生产的重要枢纽，新加坡对制药企业的研发能力、产品质量和国际合规性提出了更高的要求。
BEIJING — A group of Chinese researchers has created a gene target therapy drug for amyotrophic lateral sclerosis, or ALS.
北京——一组中国研究人员开发了一种针对肌萎缩侧索硬化症（ALS）的基因靶向治疗药物。
SineuGene Therapeutics, a biopharmaceutical company, successfully completed a clinical drug delivery attempt of adeno-associated virus vector gene therapy for ALS.
生物制药公司SineuGene Therapeutics成功完成了腺相关病毒载体基因治疗ALS的临床药物递送尝试。
"Based on the basic research achievements in neuroscience of the Tsinghua University School of Medicine, we developed the drug and completed the transformation of the research result within two years.
“在清华大学医学院神经科学基础研究成果的基础上，我们开发了该药物，并在两年内完成了研究成果的转化。
"The company is currently promoting the drug to patients with ALS, also known as Lou Gehrig's disease.
该公司目前正在向ALS患者推广该药物，也称为Lou Gehrig病。
In particular, we see unrealized potential and vast opportunities in China's increasing need for healthcare, high-quality food and drugs, solutions on environmental protection, and a digital economy, where Merck is in a sweet spot to continuously contribute with our innovative products and services.
特别是，我们看到了中国对医疗保健、高质量食品和药品、环保解决方案和数字经济日益增长的需求中未实现的潜力和巨大的机遇，默克正处于不断为我们的创新产品和服务做出贡献的最佳位置。
That also meant the drug has expanded the treatment population from late-stage to early-stage cancer patients.
这也意味着该药物已经将治疗人群从晚期癌症患者扩大到早期患者。
The supplemental new drug application for the drug in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC) has been approved by the National Medical Products Administration, the company announced Tuesday.
该公司周二宣布，国家医疗产品管理局已批准该药物与化疗联合作为围手术期治疗的补充新药申请，以及随后作为辅助治疗的单药治疗，用于治疗可切除的IIIA-IIIB期癌症（NSCLC）成年患者。
The first six indications, including as a treatment for unresectable or metastatic melanoma after the failure of standard systemic therapy, have been included in the 2023 edition of the national reimbursement drug list.
前六个适应症，包括标准全身治疗失败后不可切除或转移性黑色素瘤的治疗，已被列入2023年版的国家报销药物清单。
"Flora Zhu, director of China corporate research at Fitch Ratings, said: "China is the world's second-largest pharmaceutical market and the demand for high-quality drugs, where the global pharmaceutical companies have a competitive edge, is strong and will continue to grow, driven by China's aging population, increasing disposable incomes, growing health awareness and rising medical insurance coverage.
惠誉评级中国企业研究总监Flora Zhu表示：“中国是世界第二大制药市场，在中国人口老龄化、可支配收入增加、，健康意识的提高和医疗保险覆盖率的提高。
A novel drug production base, with an annual capacity of 250 million tablets and 550 million capsules has been put into operation, becoming the first high-end biomanufacturing project in Shanghai's Zhangjiang innovative drug industry base, Chinese biopharmaceutical company HutchMed announced on Friday.
中国生物制药公司HutchMed周五宣布，一个年产能2.5亿片、5.5亿粒胶囊的新药生产基地已投入运营，成为上海张江创新药产业基地的第一个高端生物制造项目。
Taking up an area of 43 acres, the newly completed project in Shanghai's Zhangjiang Innovation Drug Industry Base is facilitating HutchMed's pursuit of building a first-class global manufacturing center and clinical sample preparation center in China.
上海张江创新药产业基地新建成的项目占地43英亩，有助于HutchMed打造中国一流的全球制造中心和临床样品制备中心。
Being one of the city's major strategic emerging industrial projects, construction of the HutchMed's innovative drug production base started three years ago.
作为该市的重大战略性新兴产业项目之一，HutchMed的创新药物生产基地于三年前开始建设。
For example, during the China International Import Expo held in Shanghai last month, the first and only targeted drug approved in China for the treatment of chronic graft-versus-host disease (cGVHD) by French pharmaceutical company Sanofi made its Asia debut.
例如，上个月在上海举行的中国国际进口博览会期间，法国赛诺菲制药公司在中国批准的第一种也是唯一一种治疗慢性移植物抗宿主病的靶向药物首次在亚洲亮相。
Nefecon was the first-ever treatment for IgAN approved by the United States Food and Drug Administration in December 2021 and the European Medicines Agency in July 2022.
Nefecon是美国食品药品监督管理局于2021年12月和欧洲药品管理局于2022年7月批准的第一种IgAN治疗方法。
"While actively preparing for the commercial launch of Nefecon and bringing this first-in-disease therapy to patients in China as soon as possible, the company will continue to develop other innovative drug candidates in renal and auto-immune diseases to benefit more Chinese and Asian patients," he said.
他说：“在积极准备Nefecon的商业上市并尽快将这一首个疾病治疗推向中国患者的同时，该公司将继续开发其他肾脏和自身免疫疾病的创新候选药物，使更多中国和亚洲患者受益。”。
The company said that the medicine is expected to receive new drug application approval in Singapore and China's Hong Kong Special Administration soon.
该公司表示，该药有望很快在新加坡和中国香港特别行政区获得新药申请批准。
During the CIIE, Boehringer Ingelheim also exhibited a new drug candidate at the Phase-3 clinical trial for treating idiopathic pulmonary fibrosis, a rare and chronic lung disease.
在CIIE期间，勃林格殷格翰还在治疗特发性肺纤维化（一种罕见的慢性肺病）的3期临床试验中展示了一种新的候选药物。
AbbVie plans to introduce over 30 new innovative drugs or indications into China by 2030, and foster the high-quality development of the country's healthcare industry through open and diverse collaboration, Lily Dong, Vice President and General Manager of AbbVie China, said in an interview.
AbbVie中国区副总裁兼总经理Lily Dong在接受采访时表示，AbbVie计划到2030年将30多种新的创新药物或适应症引入中国，并通过开放和多样化的合作促进中国医疗保健行业的高质量发展。
"Through our participation in the CIIE, we've benefitted from China's further opening-up, gained valuable business opportunities in its dynamic healthcare market, and swiftly had our products approved and added into the reimbursement drug list," said Dong.
董说：“通过参加进博会，我们受益于中国的进一步开放，在其充满活力的医疗保健市场获得了宝贵的商机，并迅速将我们的产品批准并列入报销药物名单。”。
AbbVie has been capitalizing on the CIIE to deepen its presence in China, quickening the pace for Chinese patients to access its innovative drugs.
AbbVie一直在利用CIIE来深化其在中国的业务，加快了中国患者获得其创新药物的步伐。
At this year's event, the company will once again present its innovative JAK inhibitor Rinvoq and pioneering hematological cancer drug Venclexta, both of which received accelerated approval thanks to their debut in the previous CIIE.
在今年的活动上，该公司将再次展示其创新的JAK抑制剂Rinvoq和开创性的血液学癌症药物Venclexta，这两种药物都因在上届进博会上首次亮相而获得了加速批准。
Benefiting from the spillover effect of CIIE, these two drugs will demonstrate the potential to treat more conditions of diseases, with the hope of getting approval on related indications in China soon.
得益于CIIE的溢出效应，这两种药物将显示出治疗更多疾病的潜力，有望很快在中国获得相关适应症的批准。
Dong emphasized that China's ongoing healthcare reform and the expedited new drug approval have benefited AbbVie, with Rinvoq as a particular example, which has been approved for seven indications within only 20 months after its launch in China.
董强调，中国正在进行的医疗改革和加快的新药审批使AbbVie受益，Rinvoq就是一个特别的例子，它在中国推出后仅20个月就获得了7个适应症的批准。
She expected that the pace of new drug launch in China will continue to gain momentum supported by AbbVie's ongoing or planned involvement in over 70 clinical research programs in the country.
她预计，在AbbVie正在或计划参与中国70多个临床研究项目的支持下，中国新药上市的步伐将继续加快。
"As we continue to bring first-in-class and best-in-class innovative drugs to China, we also prioritize efforts to foster mutually beneficial external partnerships in China.
“随着我们继续将一流和一流的创新药物带到中国，我们也优先努力在中国建立互利的外部伙伴关系。
For example, Medi Cover introduced a patient welfare program to greatly reduce patients' financial burdens and improve the accessibility and affordability of innovative drugs through commercial insurance.
例如，Medi Cover推出了一项患者福利计划，通过商业保险大大减轻患者的经济负担，提高创新药物的可及性和可负担性。
For the sixth session, AstraZeneca will exhibit its achievements over the past three decades in China at its 1,000-square-meter main booth, showcasing innovative therapies and new drugs involved in such areas as tumors, cardiovascular, respiratory, digestive and rare diseases.
在第六届会议上，阿斯利康将在其1000平方米的主展位上展示其过去三十年在中国取得的成就，展示肿瘤、心血管、呼吸、消化和罕见病等领域的创新疗法和新药。
Two of its flagship innovative drugs are debuting at the CIIE this year.
该公司的两款旗舰创新药物将于今年在进博会上首次亮相。
During the expo, the company plans to announce the latest progress of its investment and business layout in China and expects to ink collaborations with several local enterprises to jointly establish world-level production bases, develop new drugs and help Chinese enterprises go global.
在博览会期间，该公司计划宣布其在中国的投资和业务布局的最新进展，并希望与几家当地企业建立合作关系，共同建立世界级的生产基地，开发新药，帮助中国企业走向世界。
In response to the country's dual carbon goals, AstraZeneca will utilize the expo to display results in promoting green and sustainable development in terms of drug research, production and operation, business models and other fields.
为响应国家的双碳目标，阿斯利康将利用博览会展示在药物研究、生产经营、商业模式等领域促进绿色可持续发展的成果。
The investment agreement aims to introduce core technologies of diabetes drugs and related production and supply chains to build Taizhou into a global production base of AstraZeneca in relation to diabetes.
该投资协议旨在引入糖尿病药物及相关生产和供应链的核心技术，将泰州打造成阿斯利康糖尿病全球生产基地。
GSK has 23 other vaccine candidates in the development stage, including a respiratory syncytial virus (RSV) vaccine, which was approved by the United States Food and Drug Administration in May for the prevention of RSV infection in people aged 60 or older.
葛兰素史克还有23种其他候选疫苗处于开发阶段，其中包括一种呼吸道合胞病毒（RSV）疫苗，该疫苗于5月被美国食品和药物管理局批准用于预防60岁或以上人群感染RSV。
The drug Sunlenca®(Lenacapavir) provides a new treatment option that only needs to be administered twice a year.
药物Sunlenca®（Lenacapavir）提供了一种新的治疗选择，每年只需给药两次。
The drug in both injection and tablet forms have been approved for market in the European Union and the US for the treatment of HIV infection in combination with other antiretrovirals in people with multi-drug resistant HIV who are heavily treatment-experienced.
该药物以注射和片剂形式已获准在欧盟和美国上市，用于与其他抗逆转录病毒药物联合治疗有丰富治疗经验的耐多药艾滋病毒患者的艾滋病毒感染。
The company said that the tablet and injection of the drug have submitted a marketing authorization application in China.
该公司表示，该药物的片剂和注射剂已提交了在中国的上市授权申请。
Shanghai Junshi Biosciences has gained approval from the United States' Food and Drug Administration for a market launch of a flagship self-developed cancer treatment, which experts said marks another milestone of domestic enterprises' innovation and production capacities.
上海君实生物科技有限公司已获得美国食品药品监督管理局的批准，推出自主研发的癌症旗舰疗法，专家表示，这标志着国内企业创新和生产能力的又一个里程碑。
In an online media conference on Monday, Yao Sheng, senior vice-president of Junshi Biosciences, said the company had signed cooperation agreements with foreign partners including Coherus, Hikma, Rxilient Biotech and Dr. Reddy's that cover more than 50 markets, and expects the drug to get greater presence worldwide following the approval from the US FDA.
在周一的一次在线媒体会议上，君实生物高级副总裁姚胜表示，该公司已与包括Cohereus、Hikma、Rxilient Biotech和Dr.Reddy’s在内的外国合作伙伴签署了涵盖50多个市场的合作协议，并预计该药物在获得美国食品药品监督管理局批准后将在全球范围内获得更大的影响力。
The Chinese biotech and its US partner Coherus BioSciences Inc jointly announced on Oct 27 that the US FDA approved Loqtorzi (toripalimab-tpzi) in combination with other drugs for the first-line treatment of adults with metastatic or recurrent locally advanced metastatic nasopharyngeal carcinoma (NPC), and as monotherapy for the treatment of adults with recurrent, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
10月27日，中国生物技术公司及其美国合作伙伴Cohereus BioSciences Inc联合宣布，美国FDA批准Loqtorzi（托帕利单抗-tpzi）与其他药物联合用于成人转移性或复发性局部晚期转移性鼻咽癌（NPC）的一线治疗，或在含铂化疗时或之后具有疾病进展的转移性NPC。
"The approval of the homegrown antibody is the first of its kind for treating NPC in the US, and that's a milestone for China's innovative medicine industry," said Xu Ruihua, president of Sun Yat-sen University Cancer Center, and the principal investigator of the drug.
“国产抗体的批准是美国首例用于治疗NPC的抗体，这对中国创新医药行业来说是一个里程碑，”该药物的首席研究员、中山大学癌症中心院长徐瑞华说。
"In the field of NPC treatment, China has a leading position, and the drug has demonstrated our innovations in treating cancer in the field of internal medicine," he added.
他补充道：“在全国人大治疗领域，中国处于领先地位，该药物展示了我们在内科治疗癌症方面的创新。”。
According to a press release from the companies, Jong Chul Park, assistant professor at Harvard Medical School and attending physician at the Center for Head and Neck Cancers at Massachusetts General Hospital Cancer Center, said that the drug, a new treatment option demonstrating the ability to significantly improve progress-free survival and overall survival of patients, should quickly emerge as the new standard of care when used in combination with chemotherapy.
根据两家公司的新闻稿，哈佛医学院助理教授、马萨诸塞州总医院癌症中心头颈癌中心的主治医师朴钟哲（Jong Chul Park）表示，该药物是一种新的治疗选择，表明有能力显着提高患者的无进展生存率和总体生存率，当与化疗联合使用时，应迅速成为新的护理标准。
Upbeat about the Chinese market, Kyowa Kirin Group, the Japanese pharmaceutical company that develops innovative specialty drugs, plans to further increase its investments and introduce a broader range of medications targeting conditions related to hematology and oncology, nephrology and rare diseases in China, said a senior executive.
一位高管表示，开发创新特效药的日本制药公司Kyowa Kirin Group对中国市场感到兴奋，计划进一步增加投资，并在中国推出更广泛的药物，针对血液学和肿瘤学、肾脏学和罕见病等相关疾病。
"To further contribute to the Healthy China 2030 initiative, a national guideline aimed at promoting overall health, she said Kyowa Kirin will accelerate the introduction of innovative drugs.
“为了进一步促进健康中国2030倡议，这是一项旨在促进整体健康的国家指导方针，她说Kyowa Kirin将加快创新药物的推出。
The company to date has successfully launched over 10 innovative drugs in China, spanning areas such as hematology and oncology, nephrology and rare diseases.
迄今为止，该公司已在中国成功推出了10多种创新药物，涵盖血液学和肿瘤学、肾脏学和罕见病等领域。
China has been stepping up efforts to improve its business environment for drug innovation.
中国一直在加大力度改善药品创新的营商环境。
In addition, among the approved products, seven are included in the National Reimbursement Drug List.
此外，在批准的产品中，有7种被列入《国家报销药品目录》。
The Taizhou base, along with another in Jiangsu's Wuxi, supplies world-class quality drugs to nearly 80 countries and regions, allowing made-in-China products to benefit patients around the globe, according to the company.
该公司表示，泰州基地和江苏无锡的另一个基地向近80个国家和地区供应世界级质量的药物，使中国制造的产品惠及全球患者。
In addition, the company is committed to working closely with healthcare stakeholders in the Guangdong-Hong Kong-Macao Greater Bay Area for the rapid introduction of new drugs, in a bid to address unmet medical needs, improve patient outcomes and support China's healthcare system, Lin added.
此外，林补充道，该公司致力于与广东-香港-澳门大湾区的医疗保健利益相关者密切合作，快速推出新药，以解决未满足的医疗需求，改善患者预后，并支持中国的医疗保健系统。
Hong Kong and Macao walk in step with the rest of the globe in terms of early usage of certain drugs for curing cancer and rare diseases.
香港和澳门在早期使用某些药物治疗癌症和罕见病方面与世界其他地区步调一致。
Meanwhile, the company can introduce drugs and medical devices used in Hong Kong and Macao public hospitals for urgent clinical use to certain hospitals in Guangdong province on a trial basis.
同时，该公司可以将香港和澳门公立医院用于紧急临床的药物和医疗器械试点引入广东省的某些医院。
The product, which received approval from the United States Food and Drug Administration in July, will be making its Asia debut at the expo.
该产品于7月获得美国食品和药物管理局的批准，将在博览会上首次在亚洲亮相。
"The number of drugs included in the National Reimbursement Drug List has significantly increased.
“列入国家报销药品目录的药品数量显著增加。
With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to introduce over 50 innovative drugs, vaccines, new indications and companion diagnostics to China in the next five years.
凭借对中国市场的长期承诺，总部位于美国的全球制药公司默沙东计划在未来五年内向中国引进50多种创新药物、疫苗、新适应症和配套诊断。
With strong local R&D capability, innovative drugs go through the R&D and approval process simultaneously in China and the global markets.
凭借强大的本土研发能力，创新药物在中国和全球市场同时通过研发和审批程序。
In addition, guidelines were launched to accelerate the landing of foreign-invested pharmaceutical projects and to optimize the drug review and approval process for MNCs in the country.
此外，还推出了加快外商投资制药项目落地的指导方针，优化跨国公司在华药品审评和审批流程。
We are witnesses of the local government's efforts in supporting R&D and innovative drug reviews and approvals.
我们见证了当地政府在支持研发和创新药物审查和批准方面所做的努力。
Working with the local healthcare community, we are able to bring our first-in-class and best-in-class drugs to the Chinese market.
通过与当地医疗保健界的合作，我们能够将一流和最佳的药物推向中国市场。
Shanghai-based biopharmaceutical company Zai Lab announced on Tuesday that the sales of its drug Vyvgart has officially started in China.
总部位于上海的生物制药公司Zai Lab周二宣布，其药物Vyvgart已正式开始在中国销售。
The drug was approved in China in late June.
该药物于6月下旬在中国获得批准。
Basil mentioned that the company recently has two blockbuster products - a medicine to treat obesity in some international markets and diabetes in some others as well as another potential drug achieving good results in Alzheimer's disease researches.
巴西尔提到，该公司最近推出了两款重磅产品——一种在一些国际市场治疗肥胖的药物，另一种在阿尔茨海默病研究中取得良好效果的潜在药物。
Basil said he expected the potential drug will become a game changer for patients.
巴西尔说，他预计这种潜在的药物将改变患者的游戏规则。
Zhu Duming, leader and chief physician of the critical care department at Shanghai Zhongshan Hospital, said that the launch of the medicine in China will help doctors tackle challenges related to clinical drug resistance.
上海中山医院重症监护科主任医师、主任医师朱杜明表示，该药物在中国的推出将有助于医生应对与临床耐药性相关的挑战。
"The company will continue to advance the approval and commercialization of other drug candidates to further address urgent unmet needs in China and the rest of Asia," he said.
他说：“该公司将继续推进其他候选药物的审批和商业化，以进一步解决中国和亚洲其他地区尚未满足的紧迫需求。”。
Besides, several of its innovative products in the areas of autoimmune, cardiovascular and kidney diseases as well as diabetes have been included in the latest version of the National Reimbursement Drug List.
此外，其在自身免疫、心血管和肾脏疾病以及糖尿病领域的一些创新产品已被列入最新版本的国家报销药物清单。
For example, government policies related to optimizing the business environment, speeding up the review of new drug approvals, and access to medical insurance helped bring our innovative health solutions to more people in China quickly," Charmeil said.
例如，与优化营商环境、加快新药审批和医疗保险相关的政府政策有助于将我们的创新健康解决方案迅速带给中国更多的人，”Charmeil说。
Doctors said many people living with HIV are under psychological pressure as they need to take the traditional antiviral drugs orally twice a day, several pills each time.
医生说，许多艾滋病毒感染者承受着心理压力，因为他们需要每天口服两次传统的抗病毒药物，每次几粒。
ViiV Healthcare's Dovato, the world's first dual drug regimen, was marketed in China in 2021.
ViiV Healthcare的Dovato是世界上第一个双药方案，于2021年在中国上市。
It was the first single tablet, dual drug treatment for HIV infection that needs to be taken just once a day, Carey said during her visit to China last week.
凯里上周访问中国时说，这是第一种每天只需服用一次的单片、双药治疗艾滋病毒感染的药物。
"As China speeds up approval of novel drugs, Chinese patients are able to get faster access to our innovative treatments.
“随着中国加快新药审批速度，中国患者能够更快地获得我们的创新治疗。
Since 2009, Bayer has introduced 19 innovative drugs with more than 30 new indications in China, data from the company showed.
拜耳公司的数据显示，自2009年以来，该公司已在中国推出19种创新药物，新适应症超过30种。
"I am really pleased to see how quickly we received the approval for our innovative drugs, and the inclusion of some of them in the country's National Reimbursement Drug List," he said.
他说：“我真的很高兴看到我们的创新药物如此迅速地获得批准，并将其中一些药物列入国家报销药物清单。”。
On July 10, Bayer and Peking University said they would extend their collaboration to foster the translation of basic research into drug discovery and development, while accelerating scientific research on cutting-edge technologies across the pharmaceutical value chain.
7月10日，拜耳和北京大学表示，他们将扩大合作，促进基础研究转化为药物发现和开发，同时加快整个制药价值链尖端技术的科学研究。
So far, Bayer and the two prestigious universities have carried out a total of 99 joint research projects on drug discovery and innovation.
到目前为止，拜耳和这两所著名大学共开展了99个药物发现和创新的联合研究项目。
With the improved drug innovation environment, 109 new drugs were approved by the National Medical Products Administration between 2018 and 2022, including 12 first-in-class drugs, according to data from the China Chamber of Commerce for Import and Export of Medicines and Health Products.
根据中国药品和保健品进出口商会的数据，随着药品创新环境的改善，2018年至2022年间，国家医疗产品管理局批准了109种新药，其中包括12种一类药物。
China remains one of our top priorities, and we will continue to bring more innovative drugs to the country. "
中国仍然是我们的首要任务之一，我们将继续为中国带来更多的创新药物。"
Since 2022, Switzerland-based Novartis has seen 100 percent of its drug development in China achieve simultaneous development with markets worldwide, significantly narrowing the time gap between launches of new drugs in China and globally, said a senior executive of the pharmaceutical company.
总部位于瑞士的诺华制药公司的一位高管表示，自2022年以来，该公司在中国的药物开发100%实现了与全球市场的同步开发，大大缩小了新药在中国和全球上市之间的时间差距。
It was a major breakthrough and the company was quite agile in this respect in the industry, said Shreeram Aradhye, president of global drug development and chief medical officer for Novartis.
诺华公司全球药物开发总裁兼首席医疗官Shreram Aradhye表示，这是一个重大突破，该公司在这方面在行业中相当灵活。
"In the future, as we're in simultaneous development mode already, more and more drugs will be introduced into China for the first time," said Aradhye during a media interview in Shanghai last week.
Aradhye上周在上海接受媒体采访时表示：“未来，由于我们已经处于同步开发模式，越来越多的药物将首次引入中国。”。
"It often used to be three or five years behind for a new drug to enter China after its launch in the global market — depending on the Chinese patient data that we were waiting for.
“过去，一种新药在全球市场上市后进入中国通常要晚三到五年——这取决于我们正在等待的中国患者数据。
He added that the company is fairly rigorous in being very aware of what therapies are available and what its peer companies are working on, and then identifies rigorously the profile of a new drug that is required for it to be competitive and bring real value to patients and the healthcare system.
他补充说，该公司非常严格地了解可用的疗法和同行公司正在研究什么，然后严格确定新药的概况，使其具有竞争力并为患者和医疗系统带来真正的价值。
Some of the therapeutic areas are also in line to help the country reduce burdens from an aging population and chronic diseases, said Rose Gao, who leads the company's drug development in China.
该公司在中国的药物开发负责人Rose Gao说，一些治疗领域也有望帮助国家减轻人口老龄化和慢性病带来的负担。
According to US industrial media Fierce Biotech, last year, the top 10 global pharmaceutical companies in terms of major business revenue cut a total of more than 50 drug development pipelines while global biopharmaceutical investment began to slow in 2022 after experiencing two years of fairly high levels during the COVID-19 pandemic.
据美国工业媒体Fierce Biotech报道，去年，全球主要业务收入排名前十的制药公司削减了总共50多条药物开发管道，而全球生物制药投资在新冠肺炎大流行期间经历了两年的高水平后，于2022年开始放缓。
Market consultancy Gartner predicts that by 2025, generative AI will account for 10 percent of all data created, compared with less than 1 percent in 2022, and could be used for a range of activities like creating software code, facilitating drug development and targeted marketing.
市场咨询公司Gartner预测，到2025年，生成性人工智能将占所有创建数据的10%，而2022年不到1%，并可用于创建软件代码、促进药物开发和定向营销等一系列活动。
Beaufort-Ipsen (Tianjin) Pharmaceutical Co Ltd inked a deal with Shenzhen Wanhe Pharmaceutical Co Ltd on Monday, in an effort to increase its drug accessibility in China.
周一，Beaufort-Ipsen（天津）制药有限公司与深圳万和制药有限公司签署了一项协议，以提高其在中国的药品可及性。
The agreement was signed to promote the early entry of Beaufort-Ipsen's new intestinal preparation drug to benefit more patients in China.
签署该协议是为了促进Beaufort Ipsen的新型肠道制剂药物尽早进入中国，使更多患者受益。
Although there are many intestinal preparation drugs, there is still a need for intestinal preparation drugs with good taste, less water, high quality and safety.
尽管肠道制剂药物很多，但仍然需要口感好、水分少、质量高、安全的肠道制剂药物。
"The intestinal preparation drug from Beaufort-Ipsen is a French product and will be listed in the Chinese market this year.
“Beaufort Ipsen的肠道制剂药物是法国产品，今年将在中国市场上市。
Under the partnership, IFC, a member of the World Bank Group and the largest global development institution focusing on the private sector of emerging markets, will provide subsidiaries of Fosun Pharma with loans totaling 50 million euros ($53.58 million) to support the construction of a manufacturing site near Abidjan, Cote d'Ivoire, that will produce anti-malaria drugs and antibacterial medicines.
根据该合作伙伴关系，国际金融公司是世界银行集团的成员，也是专注于新兴市场私营部门的最大全球发展机构，将向复星医药的子公司提供总额为5000万欧元（5358万美元）的贷款，以支持在科特迪瓦阿比让附近建造一个制造基地，这将生产抗疟疾药物和抗菌药物。
"IFC's partnership with Fosun will increase Africa's ability to manufacture essential drugs locally, helping patients more easily access high-quality, affordable medicines," he said.
他说：“国际金融公司与复星的合作将提高非洲在当地生产基本药物的能力，帮助患者更容易获得高质量、负担得起的药物。”。
As the first Chinese drug brand widely recognized in Africa, Artesun (Artesunate for Injection), independently developed and manufactured by Fosun Pharma, has treated over 56 million patients with severe malaria worldwide.
作为第一个在非洲获得广泛认可的中国药品品牌，复星医药自主研发生产的Artesun（注射用青蒿琥酯）已在全球治疗了5600多万名重症疟疾患者。
Amid an ongoing cancer drug shortage, the United States Food and Drug Administration has been working with Chinese drugmaker Qilu Pharmaceutical Co Ltd to import the oncological medication cisplatin.
在癌症药物持续短缺的情况下，美国食品药品监督管理局一直在与中国制药商齐鲁制药有限公司合作进口肿瘤药物顺铂。
This is the first time that a Chinese pharmaceutical enterprise has won the right to export drugs available in the Chinese market to address medicinal shortfalls in the US.
这是中国制药企业首次获得出口中国市场药品的权利，以解决美国的药品短缺问题。
The FDA has authorized the temporary importation of cisplatin from China in an effort to ease an acute shortage of cancer drugs in the US, according to an update posted to the agency's website.
根据FDA网站上发布的最新消息，FDA已授权从中国临时进口顺铂，以缓解美国癌症药物的严重短缺。
Qilu said in a statement on its official WeChat account that it received an urgent email from the FDA in March, calling for cisplatin supply amid US drug shortages.
齐鲁制药在其官方微信账号上的一份声明中表示，它在3月份收到了美国食品药品监督管理局的一封紧急电子邮件，呼吁在美国药品短缺的情况下供应顺铂。